A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Фаза 2
Прекращено
NCT04916002
| Заболевание | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Regeneron Pharmaceuticals |
|---|
| Статус | Прекращено |
|---|
| Участники | 77 участн. |
|---|
| Вмешательство | vidutolimod, cemiplimab |
|---|
| Дата начала | 30.11.2021 |
|---|
| Дата завершения | 31.10.2024 |
|---|
| Публикация результатов | 5.12.2025 |
|---|
Кратко
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Objective Response Rate (ORR)
Up to 31.5 Months · Percentage of participants
| Cohort A1: CMP-001+Cemiplimab for CSCC | 44.0 Percentage of participants |
|---|
| Cohort A2: CMP-001+Cemiplimab for CSCC | 5.3 Percentage of participants |
|---|
| Cohort B1: CMP-001+Cemiplimab for MCC | 46.2 Percentage of participants |
|---|
| Cohort B2: CMP-001+Cemiplimab for MCC | 6.3 Percentage of participants |
|---|
| Cohort D: CMP-001+Cemiplimab for BCC | 25.0 Percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.